ZYNE Zynerba Pharmaceuticals Inc.

5.26
-0.13  -2%
Previous Close 5.39
Open 5.55
Price To Book 1.99
Market Cap 131,240,198
Shares 24,950,608
Volume 1,224,898
Short Ratio
Av. Daily Volume 851,798
Stock charts supplied by TradingView

NewsSee all news

  1. Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

    - Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial - - Top Line Results of Pivotal CONNECT-FX Trial Expected Late in the Second Quarter of 2020 - DEVON, Pa., May

  2. Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

    DEVON, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  3. Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

    DEVON, Pa., May 22, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  4. Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic

    DEVON, Pa., May 21, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  5. Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

    DEVON, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Development to be discontinued - noted January 2018.
ZYN001
Fibromyalgia
Development to be discontinued - noted January 2018.
ZYN001
Peripheral Neuropathic Pain (PNP)
Phase 2/3 data due late-2Q 2020.
Zygel ZYN002
Fragile X syndrome
Phase 2 data released August 14, 2017 - primary endpoint not met. Noted January 2018 that development will be discontinued.
ZYN002 - STOP
Osteoarthritis
Phase 2b trial initiation postponed until after the completion of childhood neuropsychiatric studies.
ZYN002
Adult Epilepsy Patients with Refractory Focal Seizures
Phase 2 top-line data released September 18, 2019. 10/46 patients reported a serious adverse event (SAE). Intends to meet with FDA 2Q 2020 to discuss path forward.
ZYN002 BELIEVE 1
Developmental and Epileptic Encephalopathies (DEE)
Phase 2 data due 3Q 2020.
Zygel ZYN002
22q11.2 Deletion Syndrome
Phase 2 data released May 27, 2020. Trial achieved statistically significant and improvements from in all subscales of the Aberrant Behavior Checklist.
Zygel ZYN002 - BRIGHT
Autism Spectrum Disorder (ASD)

Latest News

  1. Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

    - Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial - - Top Line Results of Pivotal CONNECT-FX Trial Expected Late in the Second Quarter of 2020 - DEVON, Pa., May

  2. Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

    DEVON, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  3. Zynerba Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

    DEVON, Pa., May 22, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  4. Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic

    DEVON, Pa., May 21, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  5. Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

    DEVON, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  6. Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference

    DEVON, Pa., April 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  7. Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

    - Key Recent Clinical Milestones Include Completion of Enrollment in Pivotal CONNECT-FX Trial in Fragile X Syndrome and Phase 2 BRIGHT Trial in Autism Spectrum Disorder - DEVON, Pa., March 10, 2020 (GLOBE NEWSWIRE) --

  8. Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting

    DEVON, Pa., March 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  9. Zynerba Pharmaceuticals to Present at the 32nd Annual ROTH Conference

    DEVON, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  10. Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population

    DEVON, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  11. Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers

    - Data Presented at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - - Health State Utility Index Data Estimate the Significant Health Burden of FXS, and Suggest the Potential Benefit of

  12. Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome

    DEVON, Pa., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  13. Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol

    DEVON, Pa., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  14. Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual Meeting

    DEVON, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  15. Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome

    - Company Expects to Complete Randomization in February 2020 - - Topline Results from Pivotal CONNECT-FX Study Remain On Track for the Second Quarter of 2020 - DEVON, Pa., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Zynerba

  16. Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome

    DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  17. Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

    DEVON, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  18. Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol

    DEVON, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  19. Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

    - Positive Topline Results from BELIEVE 1 Phase 2 Trial of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies Suggest Compelling Seizure Reductions and Excellent Tolerability - -

  20. Zynerba Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

    DEVON, Pa., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  21. Zynerba Pharmaceuticals, Inc. Presenting at the Benzinga Cannabis Capital Conference in Chicago

    Chicago, Illinois--(Newsfile Corp. - October 15, 2019) - Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), will be presenting at the 5th Benzinga Cannabis Capital Conference in Chicago October 22-23 before an audience of

  22. Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    DEVON, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  23. Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel™ in Developmental and Epileptic Encephalopathies (DEE)

    - Study Achieves a 44% Median Seizure Reduction in Focal Impaired Awareness (Complex Partial) and Convulsive Seizures in DEE Patients by Month Two; Reductions were Sustained through Month Six of Treatment with Zygel - -

  24. Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms

    - Preliminary Evidence Shows that CBD May Prove to be Effective in Managing the Spectrum of Behavioral Symptoms Associated with these Conditions – - New Data Presented Today at the Society for the Study of Behavioural

  25. New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

    - Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS - - New Data Presented Today at the Society for the Study of Behavioural

  26. New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

    - Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS - - New Data Presented Today at the Society for the Study of Behavioural

  27. Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

    DEVON, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

  28. Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium

    DEVON, Pa., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric